Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Head & Neck 1Gynecologic 1

Conditions

Colorectal Neoplasms 24Stomach Neoplasms 10Pancreatic Neoplasms 10Rectal Neoplasms 9Colonic Neoplasms 9Adenocarcinoma Of Esophagus 8Esophageal Neoplasms 7Urinary Bladder Neoplasms 6Neoplasms 5Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Adenocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Cholangiocarcinoma 4Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Carcinoma, Hepatocellular 3Carcinoma 3Ovarian Neoplasms 2Melanoma 2Lung Neoplasms 2Hepatoblastoma 2Gallbladder Neoplasms 2Biliary Tract Neoplasms 2Anus Neoplasms 2Advanced Solid Tumors 2Uterine Cervical Neoplasms 1Urothelial Carcinoma of the Bladder 1Urologic Neoplasms 1

Interventions

pembrolizumab 4Cisplatin 4Fluorouracil 3Carboplatin 3Radiotherapy 2Paclitaxel 2Oxaliplatin 2Leucovorin 2Capecitabine 2tislelizumab 1spartalizumab 1lenvatinib 1durvalumab 1Surgical Procedures, Operative 1Saline Solution 1Radiation 1Levoleucovorin 1Laparoscopy 1Irinotecan 1Histamine H2 Antagonists 1Histamine Antagonists 1Fulvestrant 1Esophagectomy 1Dexamethasone 1CF regimen 1Acetaminophen 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × Fluorouracil × 30 days × Clear all
NCT06535607 2026-05-26

eVOLVE-02

AstraZeneca

Phase 2 Recruiting
257 enrolled
GastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Uterine Cervical Neoplasms

NCT04210115 2026-05-13

KEYNOTE 975

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
703 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT07554521 2026-05-11

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

BeOne Medicines

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡